Shares of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE – Get Rating) have been assigned a consensus recommendation of "Hold" from the six research firms that are covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $1.88.

Several equities analysts recently issued reports on the company. StockNews.com assumed coverage on Aeglea BioTherapeutics in a research note on Monday. They set a "hold" rating on the stock. Piper Sandler increased their price objective on Aeglea BioTherapeutics to $1.50 in a report on Tuesday, November 1st. Finally, Wells Fargo & Company upgraded Aeglea BioTherapeutics from an "equal weight" rating to an "overweight" rating and increased their price objective for the company from $1.50 to $2.00 in a report on Friday, October 28th.

Aeglea BioTherapeutics Stock Performance

NASDAQ:AGLE opened at $0.48 on Tuesday. The firm's fifty day moving average is $0.54 and its two-hundred day moving average is $0.60. Aeglea BioTherapeutics has a one year low of $0.34 and a one year high of $4.54. The firm has a market cap of $29.65 million, a price-to-earnings ratio of -0.42 and a beta of 1.66.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of AGLE. Bain Capital Life Sciences Investors LLC boosted its position in Aeglea BioTherapeutics by 87.8% in the 2nd quarter. Bain Capital Life Sciences Investors LLC now owns 5,347,689 shares of the biotechnology company's stock valued at $2,701,000 after buying an additional 2,500,000 shares during the last quarter. Pictet Asset Management SA grew its position in Aeglea BioTherapeutics by 91.6% in the 2nd quarter. Pictet Asset Management SA now owns 4,890,502 shares of the biotechnology company's stock worth $2,470,000 after purchasing an additional 2,338,068 shares during the last quarter. Nantahala Capital Management LLC boosted its holdings in shares of Aeglea BioTherapeutics by 21.1% in the second quarter. Nantahala Capital Management LLC now owns 3,877,311 shares of the biotechnology company's stock valued at $1,958,000 after acquiring an additional 676,718 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Aeglea BioTherapeutics by 283.5% in the second quarter. Renaissance Technologies LLC now owns 582,444 shares of the biotechnology company's stock valued at $294,000 after acquiring an additional 430,576 shares in the last quarter. Finally, Rock Springs Capital Management LP boosted its holdings in Aeglea BioTherapeutics by 14.8% during the first quarter. Rock Springs Capital Management LP now owns 1,811,425 shares of the biotechnology company's stock worth $4,166,000 after buying an additional 234,129 shares in the last quarter. 78.01% of the stock is currently owned by hedge funds and other institutional investors.

About Aeglea BioTherapeutics

(Get Rating)

Aeglea Biotherapeutics, Inc is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency.

See Also

• Get a free copy of the StockNews.com research report on Aeglea BioTherapeutics (AGLE)
• Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
• SoFi Technologies Smashes Earnings but Beware the Fed Decision
• Buying The Dip In Colgate-Palmolive
• Mullen Automotive On Hiring Spree, What Could That Mean?
• InterDigital Raises Its Earnings Guidance

Receive News & Ratings for Aeglea BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.